Japan's NEC has acquired Norwegian bioinformatics firm OncoImmunity for an undisclosed sum. The deal is expected to close in the second half of this year, and will see NEC's Bioinformatics division become a wholly owned subsidiary of the company. OncoImmunity develops proprietary machine learning software for use in research linked to neoantigens. Post-acquisition, it will be rebranded as a subsidiary and operate as NEC OncoImmunity.
Japan's NEC has acquired Norwegian bioinformatics firm OncoImmunity for an undisclosed sum. The move is part of NEC's strategy of using AI to identify tumour cell biomarker, or neoantigen, targets. OncoImmunity develops proprietary machine learning software for use in research linked to neoantigens. Post-acquisition, it will be rebranded as a subsidiary and operate as NEC OncoImmunity.